ARCHER 1050：在表皮生长因子受体（EGFR）突变型肺癌中达到一个重要目标？ - Suppr

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

作者信息

Piotrowska Zofia, Gainor Justin F

机构信息

Zofia Piotrowska and Justin F. Gainor, Massachusetts General Hospital, Boston, MA.

出版信息

J Clin Oncol. 2018 Aug 1;36(22):2241-2243. doi: 10.1200/JCO.2018.79.3059. Epub 2018 Jun 4.

DOI:10.1200/JCO.2018.79.3059

PMID:29864378

Abstract

摘要

相似文献

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

J Clin Oncol. 2018 Aug 1;36(22):2241-2243. doi: 10.1200/JCO.2018.79.3059. Epub 2018 Jun 4.

Dacomitinib: another option for EGFR-mutant lung cancer?

Lancet Oncol. 2014 Dec;15(13):1408-1409. doi: 10.1016/S1470-2045(14)70487-5. Epub 2014 Nov 5.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.

Drugs. 2019 Jun;79(8):823-831. doi: 10.1007/s40265-019-01115-y.

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

Lancet Oncol. 2014 Dec;15(13):1433-1441. doi: 10.1016/S1470-2045(14)70461-9. Epub 2014 Nov 5.

Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.

Drugs Today (Barc). 2019 Apr;55(4):231-236. doi: 10.1358/dot.2019.55.4.2965337.

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.

BMC Bioinformatics. 2018 Mar 7;19(1):88. doi: 10.1186/s12859-018-2093-6.

Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.

Clin Lung Cancer. 2018 Nov;19(6):484-492. doi: 10.1016/j.cllc.2018.05.007. Epub 2018 May 26.

EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1305-1310. doi: 10.1007/s00280-016-3155-y. Epub 2016 Oct 21.

Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.

Lung Cancer. 2018 Jul;121:82-90. doi: 10.1016/j.lungcan.2018.04.024. Epub 2018 May 1.

引用本文的文献

Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer.

Onco Targets Ther. 2019 Aug 15;12:6535-6548. doi: 10.2147/OTT.S198945. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献